Impact of Icosapent Ethyl on Cardiovascular Risk Reduction in Patients With Heart Failure in REDUCE‐IT

• Authors: Senthil Selvaraj, University of Pennsylvania; Deepak L. Bhatt, Harvard University; Ph. Gabriel Steg, Hôpital Bichat; Michael Miller, University of Maryland; Eliot Brinton, Utah Lipid Center; Terry Jacobson, Emory University; Rebecca A. Juliano, Amarin Pharma, Inc; Lixia Jiao, Amarin Pharma, Inc; Jean-Claude Tardif, Université de Montréal; Christie M. Ballantyne, Methodist DeBakey Heart and Vascular Center
• Journal Title: Journal of the American Heart Association
• Volume: Volume 11, Number 7
• Publisher: Wiley | 2022-04-05
• Type of Work: Article | Final Publisher PDF
• Publisher DOI: http://doi.org/10.1161/JAHA.121.024999
• Subjects: Health Sciences, Medicine and Surgery
• Keywords: eicosapentaenoic acid; heart failure; prevention

Abstract

Patients with heart failure (HF) are at high risk for atherosclerotic cardiovascular disease. Studies of atherothrombotic treatments in this population have been disappointing to date. Icosapent ethyl reduced the risk of atherosclerotic cardiovascular disease among a broad array of statin‐treated patients at elevated risk for atherosclerotic cardiovascular disease. Whether the treatment benefits of icosapent ethyl are consistent among those with HF is unknown.